For Healthcare Professionals: Multiple Myeloma

Our multidisciplinary team approach to multiple myeloma and related diseases draws on the expertise of hematologic oncologists, radiation oncologists, radiologists, pathologists, and bone marrow transplant and pain specialists, among others, who collaborate closely on each patient’s care. We have decades of experience in treating these conditions, and were among the first to recognize the therapeutic value of drugs such as thalidomide and proteasome inhibitors, as well as the predictive power of a serum-free light chain assay for assessing relapse risk. We continue our successful program in stem cell transplantation as we simultaneously test new treatments, diagnostic tools, and DNA testing approaches for projecting individual cancer response.

Refering a Patient

Call 866-218-8132
Mon–Fri, 8:30 AM–5:30 PM, ET

Find an Expert | See Clinical Trials | Request a Pathology Consult

More Science. Less Fear.
It’s Time to Change How the World Treats Cancer.

Learn how we’re making what was impossible yesterday possible today.

Pictured: Alexander Lesokhin
Multiple Myeloma Information for Your Patients

The Memorial Sloan Kettering approach to diagnosis and treatment of multiple myeloma in patient-friendly language.

E-Publications for Medical Professionals

Stay up-to-date on Memorial Sloan Kettering advances in your areas of interest.

Subscribe to OncoNotes »

Pictured: Guenther Koehne
Case Study: WT1-Specific T-Cell Responses in a Patient with Plasma Cell Leukemia and Relapsed Refractory Multiple Myeloma

Medical oncologist Guenther Koehne explains how remission was achieved using WT1-specific T-cell therapy in a patient with refractory multiple myeloma and plasma cell leukemia.

Pictured: Alexander Lesokhin
Phase I Clinical Trial of Anti-PD-1 in Hematologic Malignancy

Medical oncologist Alexander Lesokhin discusses a phase I dose escalation of an anti-PD-1 immunotherapy in patients with hematologic cancers.

Pictured: Guenther Koehne
WT1-Specific Immune Responses in Multiple Myeloma (2011 ASH Conference)

Medical Director of the Cytotherapy Laboratory Guenther Koehne discusses WT1-specific cellular immune responses in patients with relapsed multiple myeloma and high-risk cytogenetics.

Pictured: Guenther Koehne
Myeloma Immunotherapy
Pictured: Alexander Lesokhin
Trial of Anti-PD-1
Pictured: Guenther Koehne
Immune Responses